D. E. Shaw & Co., Inc. Liquidia Corp Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Liquidia Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 13,948 shares of LQDA stock, worth $153,567. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,948

Previous 24,224 42.42%

Holding current value

$153,567

Previous $357,000 53.22%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.96 - $15.71 $122,900 - $161,435	-10,276 Reduced 42.42%	13,948 $167,000
Q1 2024 May 15, 2024	SELL	$11.35 - $16.73 $305,473 - $450,271	-26,914 Reduced 52.63%	24,224 $357,000
Q4 2023 Feb 14, 2024	BUY	$5.77 - $12.19 $295,066 - $623,372	51,138 New	51,138 $615,000
Q2 2023 Aug 14, 2023	BUY	$6.63 - $9.9 $95,259 - $142,243	14,368 New	14,368 $112,000
Q2 2022 Aug 15, 2022	BUY	$3.37 - $7.55 $433,088 - $970,273	128,513 Added 36.76%	478,155 $2.09 Million
Q1 2022 May 16, 2022	SELL	$5.14 - $7.38 $98,723 - $141,747	-19,207 Reduced 5.21%	349,642 $2.51 Million
Q4 2021 Feb 14, 2022	BUY	$2.71 - $5.17 $532,325 - $1.02 Million	196,430 Added 113.93%	368,849 $1.8 Million
Q3 2021 Nov 15, 2021	BUY	$2.28 - $2.95 $61,074 - $79,021	26,787 Added 18.39%	172,419 $476,000
Q2 2021 Aug 16, 2021	BUY	$2.51 - $3.11 $248,341 - $307,706	98,941 Added 211.91%	145,632 $416,000
Q1 2021 May 17, 2021	BUY	$2.42 - $3.6 $25,596 - $38,077	10,577 Added 29.29%	46,691 $125,000
Q4 2020 Feb 16, 2021	BUY	$2.6 - $5.79 $93,896 - $209,100	36,114 New	36,114 $107,000

Others Institutions Holding LQDA

# of Institutions

163

Shares Held

36M

Call Options Held

1.79M

Put Options Held

380K

View Full List

About Liquidia Corp

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

More about LQDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account